BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 12:45 p.m. ET.
The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.
Investor Contact Alex Kane Praxis Precision Medicines investors@praxismedicines.com 617-300-8481 Media Contact Ian Stone Canale Communications Ian.stone@canalecomm.com 619-849-5388
